SCHEMBL23329265

SCHEMBL23329265

OCc1n[nH]cc1-c1cccnc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
GSK3B P49841 1/20 0.47
DYRK1A Q13627 1/20 0.47
CYP2A6 P11509 5/20 0.45
ALDH1A1 P00352 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
TDO2 P48775 2/20 0.43
VHL P40337 2/20 0.41
METAP2 P50579 1/20 0.41
SIRT3 Q9NTG7 1/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
MAPK1 P28482 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5951254 0.84 TDO2 (0.39) DYRK1AALDH1A1TDO2MAPTHPGD
SCHEMBL27475766 0.80 HRH1 (0.49) GSK3BDYRK1ACYP2A6ALDH1A1CYP1A2
SCHEMBL12969961 0.78 ROCK1 (0.35) GSK3BDYRK1A
SCHEMBL1924022 0.77 CYP2A6 (0.50) MKNK1MKNK2GSK3BDYRK1ACYP2A6
SCHEMBL4789914 0.76 CYP2A6 (0.48) GSK3BDYRK1ACYP2A6ALDH1A1CYP1A2
SCHEMBL22309816 0.74 DYRK1A (0.40) GSK3BDYRK1ATDO2ALOX15
SCHEMBL18292364 0.73 IDO1 (0.49) GSK3BDYRK1ACYP2A6ALDH1A1CYP1A2
SCHEMBL17670258 0.72 METAP2 (0.47) MKNK1MKNK2GSK3BDYRK1ACYP2A6
SCHEMBL30384675 0.72 METAP2 (0.47) MKNK1MKNK2GSK3BDYRK1ACYP2A6
SCHEMBL952491 0.72 MKNK1 (0.50) MKNK1MKNK2GSK3BDYRK1ACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO MKNK1 3973/4885MKNK2 3939/4885GSK3B 2368/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO MKNK1 3973/4885MKNK2 3939/4885GSK3B 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.